New class of fluorine-18 labeled amino acid-derived radiotracer compounds for positron emission tomography (PET) cancer imaging.
- Next generation of cancer imaging agents.
- Enhanced sensitivity to detect glioblastoma, prostate cancer and other cancers.
PET imaging is a type of nuclear medicine procedure which relies on radioactive tracers to show the metabolic activity of cells in the body. The most commonly used radiopharmaceutical is 18F-FDG (fludeoxyglucose), whose level is greatly elevated in rapidly growing malignant tumors. PET radiotracers with enhanced sensitivity to better detect glioblastoma, prostate cancer and other cancers are needed.
Emory inventors have developed a new class of fluorine-18 labeled compounds, fluorine-18-labeled 1-amino-cyclopentane-1-carboxylic acids, 1-amino-3,4-difluorocyclopentane-1-carboxylic acids ([18F]DFACPC). In vitro data show uptake of trans DFACPC enantiomers and meso anti-cis DFACPC in glioblastoma and prostate carcinoma cell lines, similar to Axumin, a standard radiotracer for PET imaging.
In vivo biodistribution studies are ongoing.